Viatris CFO Paul Campbell Sells Shares
Paul Campbell sold 50,076 shares of Viatris Inc., valued at $809,728.92, on June 25, 2026.
Key Points
- Paul Campbell, Interim CFO of Viatris Inc., sold 50,076 shares at $16.17 each, totaling $809,728.92 on June 25, 2026.
- On Sunday, Viatris Inc. shares traded near $16.33 with a market cap of about $19 billion and a forward P/E of 6.13.
- Analysts like Barclays and JP Morgan have maintained their ratings, with price targets ranging from $12 to $22.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Paul Campbell, the Interim Chief Financial Officer at Viatris Inc., sold 50,076 shares of the company on June 25, 2026. The shares were sold at an average price of $16.17, making the transaction worth about $809,728.92. This sale was part of a planned transaction under Rule 10b5-1.
Insider Buying and Selling at Viatris Inc.
Paul Campbell, who also serves as the Chief Accounting Officer and Corporate Controller, executed this planned sale. Another notable insider activity involved Corinne Le Goff, the Chief Commercial Officer, who had both purchases and sales on April 15, 2026. Le Goff sold 19,067 shares at $13.86, among other transactions.
Viatris Inc. Stock Down 0.1%
Shares of NasdaqGS:VTRS traded near $16.33 on Sunday. Viatris Inc. has a market capitalization of approximately $19 billion. It features a forward P/E ratio of 6.13 and a beta of 0.901, indicating moderate volatility. Over the past year, the stock has ranged from $8.63 to $17.53. Its 50-day moving average is $15.86, while the 200-day moving average stands at $13.10.
$VTRS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 19, 2026, Barclays maintained a 'buy' rating on Viatris with a price target of $22. JP Morgan and Truist Securities also maintained their ratings on May 8, 2026, with targets of $18 and $20, respectively. The consensus target price among analysts is about $17.81, based on eight opinions.
About Viatris Inc.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania. It operates in various regions including North America, Europe, and Asia. The company offers a wide range of prescription and generic drugs, biosimilars, and over-the-counter products. Led by CEO Scott Andrew Smith, Viatris employs around 30,000 people and focuses on providing access to high-quality medicines.
Bottom Line
Insider transactions like Paul Campbell's planned sale are closely watched by investors for potential insights into company sentiment. Viatris Inc. continues to be a significant player in the healthcare sector with a broad portfolio of products. Investors should note that 13F filings and insider sales are typically backward-looking, reflecting past actions rather than current intentions.
Get Viatris Inc. alerts
New 13F filings, insider trades, and analyst moves on $VTRS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.